{"id":30905,"date":"2025-03-29T21:43:35","date_gmt":"2025-03-29T13:43:35","guid":{"rendered":"https:\/\/flcube.com\/?p=30905"},"modified":"2025-03-29T21:43:37","modified_gmt":"2025-03-29T13:43:37","slug":"policy-analysis-shanghais-2025-pharmaceutical-procurement-regulation-and-market-implications","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30905","title":{"rendered":"Policy Analysis: Shanghai’s 2025 Pharmaceutical Procurement Regulation and Market Implications"},"content":{"rendered":"\n

Shanghai’s Medical Centralized Bidding and Procurement Affairs Management Office has released its January 2025 list of monitored pharmaceutical varieties under the public tendering and price negotiation framework. The policy, outlined in Document No. 104 of 2023, emphasizes transparency, fairness, and price rationality in inter-provincial drug procurement. This regulatory move underscores the government’s commitment to curbing excessive pricing while ensuring clinical demand and supply stability.<\/p>\n\n\n\n

Key Policy Highlights<\/strong><\/p>\n\n\n\n

    \n
  1. Yellow Line Exceedances<\/strong>: The list identifies drugs exceeding the “Yellow Line” price threshold, signaling potential overpricing. Manufacturers and healthcare institutions are advised to adjust pricing strategies to align with market benchmarks.<\/li>\n\n\n\n
  2. Fairness Assessment Failures<\/strong>: Varieties failing the fairness assessment indicate significant price deviations. These drugs face stricter scrutiny and potential exclusion from public procurement platforms.<\/li>\n\n\n\n
  3. High-Monitoring Varieties<\/strong>: Drugs with high procurement volumes and price volatility are prioritized for monitoring. Institutions are urged to leverage the “Red-Yellow-Green Line” system for real-time price alerts.<\/li>\n<\/ol>\n\n\n\n

    Market Implications for Pharmaceutical Companies<\/strong><\/p>\n\n\n\n